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Abstract Subjects with Down syndrome (DS) have
abnormalities in virtually all aspects of the immune system
and almost all will be affected with Alzheimer’s disease
(AD). It is thought that nitric oxide (NO) is involved in the
pathophysiology of AD. In the present study, including a
total of 401 elderly DS subjects, the spectrum of plasma
amino acids and neopterin was investigated and related to
development of AD. Concentrations of nearly all amino
acids in DS subjects differed signiﬁcantly from those of
healthy controls. Neopterin was increased in DS subjects,
especially in dementia. The production of NO as reﬂected
by an increased citrulline/arginine ratio (Cit/Arg ratio) was
enhanced during development of clinical dementia. Neop-
terin concentrations correlated to the Cit/Arg ratio only in
the group of prevalent demented subjects (q = 0.48,
P = 0.006). The results of this study are suggestive for an
increase in oxidative processes in DS subjects with AD.
Keywords Amino acids  Down syndrome  Neopterin 
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Introduction
Down syndrome (DS) is a common genetic disorder with a
prevalence of 1:750 and is caused by a complete or occa-
sionally partial triplication of chromosome 21. Its preva-
lence is highly dependent on maternal age at gestation. It is
well known that individuals with DS have an increased rate
of congenital and acquired medical complications includ-
ing among others thyroid gland dysfunction. Abnormalities
have been reported in virtually all aspects of the immune
system resulting in a greater susceptibility to infectious
disease. Finally, they have a higher risk for hematological
malignancies, particularly leukemia’s, and virtually all
show the neuropathological changes of Alzheimer’s dis-
ease (AD) by the age of 35–40 years. This may be due to an
increased production of the amyloid precursor protein
(Cheon et al. 2008; Lockstone et al. 2007). Onset of clin-
ical dementia is in general in the ﬁrst half of the sixth
decade. With respect to psychopathology, depression is
frequently diagnosed and shows an age related increase
(Hunter 2005).
A growing body of evidence indicates that there is an
increased oxidative stress in AD brains and it is hypothe-
sized that nitric oxide (NO) can be related to many of the
pathophysiological mechanisms of AD (Akomolafe et al.
2006; Moreira et al. 2008). The presence of any stimulant
that leads to an overproduction of NO will probably cause
neuronal damage (Akyol et al. 2004). The biologically
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DOI 10.1007/s00726-009-0300-5active molecule NO is formed by the conversion of
L-arginine to L-citrulline, a reaction catalyzed by the
enzyme NO synthase. In this process tetrahydrobiopterin
(BH4) is a necessary cofactor. We have shown that the
ratio of the plasma concentrations of citrulline (Cit) and
arginine (Arg), the so-called Cit/Arg ratio, can be regarded
as an index of NO synthesis (Fekkes et al. 2007).
One of the key players in the production of NO in AD
may be the inﬂammation and immune activation that
characterize the pathology of AD. These processes may
play an important role in the development and progression
of dementia (McGeer and McGeer 2004). Brain inﬂam-
mation is mainly caused by activation of glia cells that
produce a variety of pro-inﬂammatory and neurotoxic
factors, including free radicals such as NO (Bernstein et al.
2005; Sharma et al. 2007). These processes may also be
relevant for persons with DS. We recently found that
neopterin, which is an indicator for systemic inﬂammation
and immune activation, increases with age in these subjects
and is associated to the risk of dementia (Coppus et al.
2009). Others have found that neopterin is increased in the
brain and the plasma of patients with AD and other neu-
rodegenerative disorders (Hull et al. 2000; Murr et al.
2003).
It has become clear that amino acids are not only
essential for various metabolic pathways such as the syn-
thesis of the major neurotransmitters. In addition, amino
acids are involved in immune responses (Li et al. 2007;
Mircher et al. 1997). Probably of special relevance are the
so-called branched-chain amino acids (BCAA) that
comprise the three essential amino acids: L-leucine, L-iso-
leucine and L-valine. In experimental conditions, adminis-
tration of BCAA was found to improve immune function
(Kakazu et al. 2007). In our previous study in healthy DS
persons, wide spread differences in nearly all amino acids
were found as compared to healthy control subjects with
signiﬁcant lower levels of the essential amino acids
(Coppus et al. 2007).
The present study was designed to assess the putative
differences in plasma levels of amino acids and neopterin
in a large cohort of DS individuals with and without
dementia.
Methods
Study population
Over a period of 4 years a community based sample of 401
individuals with DS, age 45 years and older, from the
Southern and South-Western part of the Netherlands was
composed. Recruitment procedures and the ethical protocol
are described in detail elsewhere (Coppus et al. 2006,
2007). The sample comprises 151 women and 250 males
with a mean age of 52 ± 5.1 years (Table 1). In 232
subjects, the diagnosis DS was conﬁrmed by cytogenetic
analysis. In the remaining, the diagnosis was based on the
characteristic phenotype.
The study population was divided into two birth cohorts
based on the subject’s age at the reference date. The birth
Table 1 General characteristics
All Healthy
a Demented
b Depression
c Epileptic
d
All 401 persons 130 84 38 34
Sex n (%)
Women 151 (37.7) 41 (31.5) 32(38.1) 19 (50) 11(32.4)
Men 250 (62.3) 89 (68.5) 52 (61.9) 19 (50) 23 (67.6)
Age start, mean (±SD) 51.6 (5.1) 49.9 (3.9) 53.2 (5.7) 50.3 (3.3) 51.3
Level of ID, n (%)
Severe/profound 138 (34.4) 40 (30.8) 34 (40.5) 15 (39.5) 13 (38.2)
Moderate/mild 216 (53.9) 68 (52.3) 46 (54.8) 18 (47.4) 17 (50)
Living situation
Institutionalized 247 (61.6) 79 (60.8) 50 (59.5) 32 (84.2) 22 (64.7)
Community living 154 (38.4) 51 (39.2) 34 (40.5) 6 (15.8) 12 (35.3)
Dementia status, n (%)
Demented at the start 61 (15.2) 30 (35.7)
New demented at follow-up 79 (19.7) 54 (64.3)
a Healthy persons, without dementia, or symptoms of depression and/or epilepsy
b Demented persons without symptoms of depression and/or epilepsy
c Depressive persons without symptoms of dementia and/or epilepsy
d Persons with epilepsy, without dementia and/or depressive symptoms
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123cohorts distinguishes patients who were 60 years or older
(born before 1947; n = 88) and those who were younger
than 60 years (born after 1947; n = 313) at the reference
date January 1, 2007. To deﬁne syndrome speciﬁc differ-
ences, the group of subjects with DS (n = 401) was
compared with a group of 48 age and sex-matched healthy
controls of the general population (source lab data, female
16, male 32, mean age 50.2, SD 9.1 years). For neopterin,
data were available for 28 control subjects.
Separate analyses were performed comparing individu-
als who were demented at baseline (prevalent demented)
with those who developed dementia at follow-up (incident
demented) and those who remained nondemented during
follow-up.
Clinical assessment
At baseline, assessment included an extensive interview
with relatives, caregivers and the responsible physician in
order to ascertain the medical history and daily function-
ing. In addition, all subjects had a thorough physical and
neurological examination.
The premorbid level of intellectual disability (ID) was
derived from the medical records and classiﬁed according
to the ICD-10 (World Health Organisation 1992). In
addition, a diagnosis of AD was made based on the ICD-10
criteria and the guidelines of the IASSID (Aylward et al.
1997; Burt and Aylward 2000). All subjects were screened
annually with a mean follow-up of 4.5 years. Patients who
met the diagnostic criteria of AD at baseline or during
follow-up, were monitored every 6 months. A probable
diagnosis of depressive disorder was made by the respon-
sible physician or the consultant psychiatrist. Epilepsy was
diagnosed by a neurologist or the responsible physician.
Level of ID and living situation as an expression of general
functioning are presented in Table 1.
The study population was divided into four subgroups
according to the presence of only dementia (n = 84), only
depression (n = 38) or only epilepsy (n = 34) and healthy
DS persons (n = 130). The ratio for this subclassiﬁcation
was that the use of anti-epileptics and antidepressants might
bias the results. At baseline, of the 401 DS subjects included
in this study, 61 had a diagnosis of dementia, of whom 23
with epilepsy. Of the nondemented persons 64 had a diag-
nosis of epilepsy resulting in a group of 276 nondemented
subjects without epilepsy at the start of the study.
Biochemical analyses
Plasma amino acids were analyzed by high-performance
liquid chromatography using pre-column derivatization
with o-phthaldialdehyde (Fekkes et al. 1995). The trypto-
phan-ratio was calculated by dividing the total tryptophan
level times 100 by the sum of the other large neutral amino
acids, i.e., valine, isoleucine, leucine, tyrosine (Tyr) and
phenylalanine (Phe), which compete for the transport of
tryptophan through the blood–brain barrier. The Tyr ratio
was calculated in the same manner by substituting trypto-
phan for Tyr. The value of aromatic amino acids comprises
the summed concentrations Phe, Tyr and tryptophan, and
the value of BCAA is the sum of the concentrations of
leucine, isoleucine and valine. The Phe/Tyr ratio was cal-
culated to serve as an estimate of BH4 activity. Plasma
concentration of neopterin was determined as described
previously (Hoekstra et al. 2001).
Amino acids could be measured in 401 subjects and
neopterin in 394 subjects
Statistical analysis
Univariate analyses of variance and Chi-square analyses
were used to determine whether missing data were asso-
ciated with age, sex and level of ID; no signiﬁcant effects
were found. In descriptive analyses, data were reported as
mean or numbers. Not all data showed normal distribution,
and therefore statistical analyses were made using the
nonparametric Mann–Whitney U test for comparison of
groups. When analyzed as continuous variables, as in the
partial correlation analyses, variables were natural log
transformed. P values were corrected for multiple
comparisons.
Results
During the follow-up period a total of 80 subjects died, of
whom 61 (76.3%) were demented. As can be inferred from
Table 2, plasma concentrations of nearly all biochemical
parameters, are signiﬁcantly different between healthy
controls and all individuals with DS. Only a few differ-
ences are found in the plasma concentration of the amino
acids between the four subgroups, i.e., healthy, demented,
depressive and epileptic persons. Signiﬁcant differences
(P\0.05) are found for taurine, phenylalanine and neop-
terin in that the levels of these parameters are increased in
the demented group as compared to the healthy DS group.
The increased level of taurine is present mainly in the
incident demented group as can been seen in Table 3.I n
the epileptic subgroup only the tryptophan ratio is found to
be decreased as compared to the other subgroups.
From Table 3, it can be inferred that in the group of
prevalent demented subjects, excluding those with
epilepsy, a signiﬁcantly higher neopterin concentration
(P = 0.05) and a lower Cit/Arg ratio (P = 0.006) are
found as compared to the group of nondemented subjects.
The plasma concentration of taurine is signiﬁcantly higher
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123in the incident demented as compared with the nonde-
mented (P = 0.002) and as compared with the prevalent
demented subjects (P = 0.003). In the group of incident
demented subjects, a signiﬁcantly higher Cit/Arg ratio is
found as compared to the group of prevalent demented
subjects (P = 0.003).
After adjusting for age, excluding those with epilepsy,
there is a high correlation between neopterin and the Cit/
Arg ratio in the group of prevalent demented subjects
(n = 38): q = 0.45; P = 0.006, but not in the incident
demented cases (n = 64): q = 0.18; P = 0.16 or in the
nondemented (n = 276): q = 0.08; P = 0.24. There is a
signiﬁcant correlation between neopterin and the Cit/Arg
ratio in the total group of demented subjects (n = 84):
q = 0.23; P = 0.04).
By comparing the two age subgroups, born before and
after 1947, we see that the concentrations of neopterin and
the tyrosine ratio are increased with age whereas the levels
of BCAA, taurine and tryptophan are decreased in the older
group (data not shown). After controlling for dementia only
tryptophan (q =- 0.11, P = 0.03) and neopterin is sig-
niﬁcantly correlated with age (q = 0.18, P\0.001).
Discussion
In the present study, including a large sample of DS sub-
jects with or without dementia, plasma concentrations of
nearly all biochemical parameters differ signiﬁcantly from
healthy controls. The decreased tryptophan ratio is
explained most likely by the frequent use of anti-epileptics.
Concentrations of neopterin and the tyrosine ratio are
increased with age whereas the levels of BCAA, taurine
and tryptophan are decreased in the older group. These
ﬁndings are consistent with those reported previously in a
small group of healthy DS subjects (Coppus et al. 2007).
With respect to neopterin, a marked increase is found in
the total group as compared to healthy controls, that further
increases in the demented group. In the group of prevalent
dementia the enhanced concentration of neopterin is sig-
niﬁcantly correlated with a decreased Cit/Arg ratio. This
ﬁnding is may be explained by an increase in oxidative,
inﬂammatory or neurodegenerative processes in dementia.
An explanation for a decreased Cit/Arg ratio in this con-
dition may be a reduced bioavailability of BH4, which is
the cofactor for NO synthesis and also for the conversion of
Table 2 Comparing the demented, depressive and epileptic persons with Down syndrome with the healthy persons with Down syndrome
Healthy
controls
All Down
syndrome
Healthy Down
syndrome
Demented Down
syndrome
Depressive Down
syndrome
Epileptic Down
syndrome
n = 48 n = 401 n = 130 n = 84 n = 38 n = 34
Citrulline (lM) 34.23 (8.8) 44.95 (13.6)
a 45.89 (13.2) 46.90 (13.9) 45.42 (13.5) 44.50 (12.7)
Arginine (lM) 68.02 (24.3) 74.27(21.8) 74.49 (21.1) 75.26 (19.5) 79.89 (30.2) 78.18 (19.1)
Taurine (lM) 42.88 (7.6) 52.52 (13.0)
a 51.28 (12.0) 55.39 (12.3)
b 55.00(14.8) 54.00 (12.8)
Tyrosine (lM) 71.04 (17.3) 61.77 (16.1)
a 61.00 (15.2) 64.02 (15.5) 63.00 (17.1) 63.35 (18.5)
Valine (lM) 286.21 (59.7) 232.48 (60.1)
a 231.76 (60.6) 242.38 (60.4) 230.89 (54.9) 235.65 (50.3)
Methionine (lM) 32.04 (6.4) 24.98 (6.2)
a 24.99 (5.4) 25.94 (7.2) 25.45 (6.3) 25.35 (6.5)
Tryptophan (lM) 50.38 (9.1) 41.70 (10.2)
a 42.83 (9.4) 42.89 (9.3) 44.29 (10.1) 39.79 (9.8)
Phenylanaline (lM) 63.06 (9.9) 60.15 (14.1) 58.68 (12.7) 62.50 (13.1)
b 62.53 (13.6)
b 60.74 (14.9)
Isoleucine (lM) 82.69 (24.1) 64.13 (17.5)
a 63.87 (17.0) 66.31 (18.0) 63.58 (17.7) 66.65 (14.0)
Leucine (lM) 148.48 (31.8) 125.06 (29.3)
a 125.97 (28.5) 127.55 (29.2) 127.13 (30.3) 126.47 (23.7)
Tryptophan ratio 7.89 (1.5) 7.81 (1.5) 8.07 (1.4) 7.77 (1.4) 8.26 (1.5) 7.23 (1.4)
b
Tyrosine ratio 11.33 (2.1) 11.98 (2.5) 11.82 (2.4) 12.01 (2.6) 12.03 (2.4) 12.12 (3.1)
Phe/Tyr 0.91 (0.1) 0.99 (0.2)
a 0.98 (0.1) 0.99 (0.1) 1.02 (0.2) 0.98 (0.2)
Cit/Arg 0.55 (0.2) 0.63 (0.2)
a 0.64 (0.2) 0.63 (0.2) 0.62 (0.3) 0.59 (0.2)
Neopterin (nM) 17.3 (3.6) 25.18 (11.0)
a 23.40 (8.7) 26.35 (12.2)
b 24.03 (14.9) 24.22 (11.5)
BCAA 517.37 (111.2) 421.67 (104.3)
a 421.60 (103.8) 436.24 (104.7) 421.60 (103.8) 428.76 (84.9)
AAA 184.48 (30.2) 163.61 (36.3)
a 162.51 (34.1) 169.42 (34.6) 169.81 (36.6) 163.88 (37.2)
LNAA 701.85 (135.2) 528.28 (133.8)
a 584.11 (131.6) 605.65 (130.0) 591.42 (131.5) 592.64 (114.5)
Values are mean (standard deviation)
Tryptophan ratio tryptophan/LNAA ratio, tyrosine ratio tyrosine/LNAA ratio, Phe/Tyr phenylanaline/tyrosine ratio, Cit/Arg citrulline/arginine
ratio, BCAA summed concentration of Leucine, Isoleucine and Valine lM/l, AAA summed concentration of phenylanaline, tyrosine, tryptophan
lM/l, LNAA large neutral amino acids: summed concentration of phenylalanine, tyrosine, tryptophan, valine, leucine and isoleucine lM/l
a Mann–Whitney U-test, P\0.05 healthy controls compared with the total group of persons with Down syndrome
b Mann–Whitney U-test, P\0.05 compared with the group of healthy persons with Down syndrome
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123phenylalanine to tyrosine. This is in line with the increased
phenylalanine levels in the demented as compared to the
healthy DS subjects. Possible mechanisms for the impaired
bioavailability of BH4 are oxidation of the labile substance
BH4 due to the oxidative stress and/or depletion of BH4
due to the higher neopterin synthesis at the expense of BH4
(Ploder et al. 2008; Shi et al. 2004). Since the Cit/Arg ratio
is signiﬁcantly higher in the incident demented cases and
assuming that this ratio is a good reﬂection of NO synthesis
indeed, it can be hypothesized that the production of NO is
enhanced during the early development of dementia.
The plasma concentration of taurine is increased espe-
cially in the subgroup of incident dementia (Table 3). The
ﬁnding of an increased level of taurine may be syndrome
speciﬁc since similar observations have been reported
previously (Coppus et al. 2007; Mircher et al. 1997). It has
been suggested that taurine may prevent neurotoxicity of
beta-amyloid (Louzada et al. 2004) and may decrease beta-
amyloid aggregation (Santa-Maria et al. 2007).
The BCAA concentration is not different in the various
subgroups but decreases with age. Since several decades it
has been suggested from animal studies that a lower plasma
level of BCAA may result in immune impairment (Jose and
Good 1973; Li et al. 2007).Whether the observation of
diminished BCAA in the group of older DS subjects
reﬂects a syndrome speciﬁc impaired immune function is
not clear. This may also be the consequence of dietary
factors albeit that both in the present study as in the pre-
vious one, a large difference between healthy controls and
DS subjects was found in the BCAA levels.
In conclusion, the results of the present study demon-
strate again that plasma levels of nearly all measured
amino acids in DS subjects differ substantially from those
in healthy controls. Moreover, in demented DS individuals
an additional increase of taurine is observed, while during
development of clinical dementia changes in levels of
biochemical parameters related to NO metabolism and
oxidative stress occur.
Table 3 Comparing mean concentrations, nondemented, prevalent demented and incident demented persons with Down syndrome without
epilepsy
Nondemented
at baseline
Prevalent demented
at baseline
Incident demented
during follow-up
n = 276 n = 38 n = 64
Citrulline (lM) 45.99 (13.4) 43.84 (13.9) 48.30 (13.3)
Arginine (lM) 73.71 (21.9) 78.58 (19.9) 73.70 (19.1)
Taurine (lM) 52.88 (12.6) 49.82 (11.8) 56.81 (12.8)
b,c
Tyrosine (lM) 61.94 (15.7) 64.26 (18.1) 64.83 (13.5)
Valine (lM) 234.83 (60.9) 228.89 (62.7) 247.20 (56.6)
Methionine (lM) 25.25 (5.9) 25.66 (7.7) 26.19 (6.4)
Tryptophan (lM) 43.05 (9.5) 41.50 (10.6) 43.72 (8.1)
Phenylanaline (lM) 60.57 (13.3) 61.74 (14.9) 63.09 (11.5)
Isoleucine (lM) 64.49 (18.4) 63.05 (15.8) 66.97 (18.2)
Leucine (lM) 126.56 (30.2) 122.16 (27.8) 129.25 (28.4)
Tryptophan ratio 8.02 (1.4) 7.77 (1.5) 7.82 (1.3)
Tyrosine ratio 11.88 (2.3) 12.64 (3.5) 11.97 (1.9)
Phe/Tyr 0.99 (0.1) 0.98 (0.2) 0.98 (0.1)
Cit/Arg 0.65 (0.2) 0.56 (0.1)
a 0.66 (0.2)
b
Neopterin (nM) 24.74 (10.1) 28.78 (14.4)
a 25.03 (9.8)
BCAA (lM) 425.87 (107.2) 414.10 (103.6) 443.42 (100.4)
AAA (lM) 165.56 (35.2) 167.50 (39.4) 171.64 (30.0)
LNAA (lM) 591.43 (136.4) 581.60 (129.9) 615.06 (124.3)
Values are mean (standard deviation)
Tryptophan ratio tryptophan/ LNAA ratio, tyrosine ratio tyrosine/LNAA ratio, Phe/Tyr phenylanaline/tyrosine ratio, Cit/Arg citrulline/arginine
ratio, BCAA summed concentration of leucine, isoleucine and valine lM/l, AAA summed concentration of phenylanaline, tyrosine, tryptophan
lM/l, LNAA large neutral amino acids: summed concentration of phenylalanine, tyrosine, tryptophan, valine, leucine and isoleucine lM/l
a Mann–Whitney U-test, P\0.05 prevalent demented compared with the group of nondemented persons with Down syndrome
b Mann–Whitney U-test, P\0.05 incident demented compared with the group of prevalent demented persons with Down syndrome
c Mann Whitney U-test, P\0.05 incident demented compared with the group of nondemented persons with Down syndrome
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